Direct suppression of human synovial cell proliferation in vitro by salazosulfapyridine and bucillamine

Journal of Rheumatology

Volumn 23, Issue 1, 1996, Pages 65-70

  Aono, Hiroyuki ^a,b   Hasunuma, Tomoko ^a   Fujisawa, Koushi ^a,b   Nakajima, Toshihiro ^a   Yamamoto, Kazuhiko ^a   Mita, Shiro ^b   Nishioka, Kusuki ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Bucillamine; DMARD; Rheumatoid arthritis; Salazosulfapyridine; Synovial cell proliferation

Indexed keywords

BUCILLAMINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; BASE SEQUENCE; CELL DIVISION; CELLS, CULTURED; CYSTEINE; DRUG COMBINATIONS; HUMANS; INTERLEUKINS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; SULFASALAZINE; SYNOVIAL MEMBRANE;

EID: 0030030746     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Harris ED Jr: Recent insights into the pathogenesis of the proliferative lesion in rheumatoid arthritis. Arthritis Rheum 1976;19:68-72.
2. Shiozawa S, Tokuhisa T: Contribution of synovial mesenchymal cells to the pathogenesis of rheumatoid arthritis. Semin Arthritis Rheum 1992;21:267-73.
3. Bucala R, Ritchlin C, Winchester R, Cerami A: Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. J Exp Med 1991;173:569-74.
4. Goto M, Sasano M, Yamanaka H, et al; Spontaneous production of an interleukin 1-like factor by cloned rheumatoid synovial cells in long-term culture. J Clin Invest 1987;80:786-96.
5. Guerne PA, Zuraw BL, Vaughan JH, Carson DA, Lotz M: Synovium as a source of interleukin 6 in vitro: Contribution to local and systemic manifestations of arthritis. J Clin Invest 1989;83:585-92.
6. Schmidt JA, Mizel SB, Cohen D, Green I: Interleukin 1, a potential regulator of fibroblast proliferation. J Immunol 1982;128:2177-82.
7. Butler DM, Piccoli DS, Hart PH, Hamilton JA: Stimulation of human synovial fibroblast DNA synthesis by recombinant human cytokines J Rheumatol 1988;15:1463-70.
8. Gitter BD, Labus JM, Lees SL, Scheetz ME: Characteristics of human synovial fibroblast activation by IL-1β and TNF-α. Immunology 1989;66:196-200.
9. 2 production, in human synovial fibroblasts. Proc Natl Acad Sci USA 1991;88:7180-4
10. Hamilton JA, Butler DM, Stanton H: Cytokine interactions promoting DNA synthesis in human synovial fibroblasts. J Rheumatol 1994;21:797-803.
11. Kessler DJ, Duyao MP, Spicer DB, Sonenshein GE: NF-κB-like factors mediate interleukin 1 induction of c-myc gene transcription in fibroblasts. J Exp Med 1992;176:787-92.
12. Lafyatis R, Remmers EF, Robarts AB, Yocum DE, Sporn MB, Wilder RL: Anchorage-independent growth of synoviocytes from arthritic and normal joints: Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids. J Clin Invest 1989;83:1267-76.
13. Matsubara T, Hirohata K: Suppression of human fibroblast proliferation by D-penicillamine and copper sulfate in vitro Arthritis Rheum 1988;31:964-72.
14. Paulus HE, Scott DL, Edmonds JP: Classification of antirheumatic drugs: A new proposal. Arthritis Rheum 1992;35:364-5
15. Abe C: Clinical evaluation of immunomodulators. Int J Immunother 1985;1:7-10.
16. van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB: Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036-8.
17. McConkey B, Amos RS, Butler EP, Crockson RA, Crockson AP, Walsh L: Salazopyrine in rheumatoid arthritis. Agents Actions 1978;8:438-41.
18. Nishioka K: Insights into new potential combined therapy for active rheumatoid arthritis. In: Nasution AR, Darmawan J, Isbagio H, eds. APLAR Rheumatology. London: Churchill Livingstone, 1992:313-4.
19. Wilke WS, Sherrer YR, Clough JD: Combination chemotherapy for severe rheumatoid arthritis. Intern Med Specialist 1989;10:59-16.
20. Yasuda M, Sakai K, Oribe M, et al: Efficacy of additive DMARD therapy in patients with rheumatoid arthritis. Double blind controlled trial using bucillamine and placebo with maintenance doses of gold sodium thiomalate. J Rheumatol 1994;21:44-50.
21. Fujiwara M, Mitsui K, Yamamoto I: Inhibition of proliferation responses and interleukin 2 products by salazosulfapyridine and its metabolites. Jpn J Pharmacol 1990;54:121-31.
22. Goto M, Sasano M, Nishioka K: Decrease in disease activity and concomitant increase in the percentage of peripheral blood suppressor T cells in rheumatoid arthritis by a newly synthesized slow-acting anti-rheumatic drug (bucillamine). Int J Immunopharmacol 1989;11:327-31.
23. 2 spontaneously in longterm culture. J Rheumatol 1990;17:1299-302.
24. Hashimoto K, Lipsky PE: Immunosuppression by the disease modifying antirheumatic drug bucillamine: Inhibition of human T lymphocyte function by bucillamine and its metabolites. J Rheumatol 1993;20:953-7.
25. Hayashi M, Matsunaga K, Okahara A, Mita S: Effect of bucillamine (SA96) on type II collagen induced arthritis in rats. J Rheumatol 1991;18:691-5.
26. Hirohata S, Lipsky PE: Comparative inhibitory effects of bucillamine and D-penicillamine on the function of human B cells and T cells. Arthritis Rheum 1994;37:942-50.
27. Klareskog L, Holmdahl R, Goldschmidt T, Björk J: immunoregulation in arthritis: A review on synovial immune reaction in RA and in some experimental animal models for arthritis. Scand J Rheumatol 1987;(suppl)64:7-15
28. Mita S, Matsunaga K: Differences in the effects of antirheumatic drugs, bucillamine and D-penicillamine, on mitogen-induced proliferation of mouse spleen cells. Agents Actions 1990;30:363-8
29. Okamoto M, Sasano M, Goto M, et al: Suppressive effect of antirheumatic drugs on interleukin-1β release from human peripheral blood monocytes. Int J Immunopharmacol 1991;13:39-13.
30. Sasano M, Goto M, Nishioka K: Modulatory effect of bucillamine (SA96) on interleukin-1- and/or -2-induced proliferation of T lymphocytes. Agents Actions 1990;31:285-9.
31. Sasano M, Nakata K, Mita S: Inhibitory effects of bucillamine (SA96) on interferon-γ and interleukin 2 production in human peripheral blood mononuclear cells. Int J Immunother 1991;7:87-94.
32. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
33. Saiki RK, Gelefand DH, Stoffel S, et al: Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1987;239:497-91.
34. Southern EM: Detection of specific sequence among DNA fragments separated by gel electrophoresis. J Mol Biol 1975;98:503-17.
35. Nakajima T, Aono H, Hasunuma T, et al: Overgrowth of human synovial cells driven by the human T cell leukemia virus type I tax gene J Clin Invest 1993;92:186-93.
36. Muijsers AO, van de Stadt RJ, Henrichs AMA, ven der Korst JK: Determination of D-penicillamine in serum and urine of patients with rheumatoid arthritis. Clin Chim Acta 1979;94:173-80
37. Sugawara S, Ishigami M, Kageyama T: Phase I study of N-(2-mercapto-2-methylpropiony)-L-cystcine (SA96). II. Continuous 6-day administration study. Rinsho Yakuri 1985;16:621-30.
38. Klotz U: Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet 1985;10:285-302.
39. Farr M, Kitas G, Bacon PA: Sulphasalazine in rheumatoid arthritis. Combination therapy with D-penicillamine or sodium aurothiomalate. Clin Rheumatol 1988;1:242-8.
40. Greenberg ME, Ziff EB: Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene. Nature 1984;311:433-8.
41. Kuroki Y, Shiozawa S, Yoshihara R, Hotta H: The contribution of human c-fos DNA to cultured synovial cells: A transfection study J Rheumatol 1993;20:422-8.
42. Tan PLJ, Farmiloe S, Yeoman S, Watson JD: Expression of the interleukin 6 gene in rheumatoid synovial fibroblasts. J Rheumatol 1990;17:1608-12.
43. Keffer J, Probert L, Cazlaris H, et al: Transgenic mice expressing human tumor necrosis factor: A predictive genetic model of arthriti EMBO J 1991;10:4025-31.
44. Aono H, Fujisawa K, Takahashi M, Hasunuma T, Yamamoto K, Nishioka K: Augmentation of NF-κB by TNF-α in rheumatoid synovial cells (abstr) Arthritis Rheum 1994;(suppl 9)37:S310.